Last updated: July 23, 2026
Knoa Pharma, LLC sued Accord Healthcare Inc. in the U.S. District Court for the Eastern District of Texas (case 5:24-cv-00284) in 2024. The matter is a Hatch-Waxman patent dispute tied to generic development and FDA marketing approval. The case record available in this prompt does not include the patent list, asserted claims, infringement theories, claim construction briefs, scheduling order, or any docketed settlement or final disposition. Without those case-specific documents, a complete and accurate litigation summary and patent-claims analysis cannot be produced.
What is Knoa Pharma, LLC v. Accord Healthcare Inc. (5:24-cv-00284) and what is it about?
A plaintiff-side Hatch-Waxman infringement action typically alleges that a proposed generic product infringes one or more Orange Book-listed patents for a reference-listed drug and that the ANDA (or amendments) includes Paragraph IV certifications (or carve-outs) supporting validity and non-infringement positions.
What filings determine scope in 5:24-cv-00284?
- Complaint (identifies asserted patents, claims, and product)
- Answer (denies, asserts defenses, and sometimes counterclaims)
- Early claim-construction / Markman-related filings (if set)
- Infringement contentions and noninfringement/invalidity contentions (often disclose theory)
- Scheduling order and discovery plan
- Status reports and any settlement filings (if they occur)
What patents are at issue in this case?
The prompt does not provide the asserted patent numbers, filing/expiration dates, or Orange Book listing details. Those are necessary to analyze claim scope, expiration-driven leverage, and litigation posture.
Case posture elements that require docket-level details
- Whether Knoa asserted method-of-use, formulation, or device-like product features
- Whether Accord challenged validity via anticipation/obviousness and which references were cited
- Whether the case involves willful infringement allegations or pricing/damages theories
- Whether the case was stayed pending PTAB proceedings or intertwined with other suits
What patents protect the reference drug in Knoa v. Accord and how strong is that estate?
A defensible “estate strength” assessment requires:
- the full asserted set of patents
- claim types (composition, formulation, method, use, manufacturing)
- prosecution history signals and claim breadth
- remaining patent term at the time of suit and at likely generic launch windows
- any overlaps with other litigations involving the same ANDA
This information is not present in the prompt, so a patent-estate strength analysis cannot be completed.
What infringement theories are typically alleged in Hatch-Waxman suits like this, and which ones apply here?
Standard infringement-theory buckets include:
- Literal infringement of composition or method-of-use claims
- Infringement under doctrine of equivalents
- Product-by-process arguments (if manufacturing-process claims are asserted)
- Device/delivery-system theory (if formulation or delivery design is claimed)
Which theories are actually pleaded and supported in 5:24-cv-00284 cannot be determined without the complaint and infringement contentions.
When does exclusivity or patent term typically expire in ANDA litigation, and what does it mean for 5:24-cv-00284?
In Hatch-Waxman disputes, timing drives leverage through:
- patent expiration dates (hard stop)
- 30-month stay mechanics triggered by Paragraph IV notices (unless forfeited)
- pediatric exclusivity or pediatric extension effects (if applicable)
- regulatory milestones such as ANDA approval dates and tentative approval
This requires the specific patent list and the Orange Book status of the reference product. Those inputs are not included in the prompt.
Is there a Paragraph IV challenge in this case, and what does it signal procedurally?
Paragraph IV certifications generally signal:
- the ANDA seeks approval before patent expiration
- the proposed generic is alleged to infringe the asserted patents
- the generic certifies invalidity, non-infringement, or both
Determining whether Paragraph IV is present and which patents were certified is not possible without the ANDA certification details or complaint allegations.
Has Knoa Pharma and Accord Healthcare settled or is the case active?
Settlement or disposition information comes from:
- docket entries (stipulations of dismissal, consent judgments)
- joint status reports
- settlement announcements tied to court filings
No docket disposition is provided in the prompt, so case status cannot be stated.
What generic entry risks exist for Accord Healthcare if Knoa wins or loses?
Entry risk is driven by:
- injunction scope (which patents, which claims, which product configurations)
- design-around potential (especially if formulation or method claims are asserted)
- time remaining on asserted patents
- whether non-infringement/invalidity defenses succeed
A product-specific risk profile requires:
- the accused ANDA product and dosage form
- the specific asserted claims and remedies sought
Those details are absent from the prompt.
What FDA pathway issues could affect timing in 5:24-cv-00284?
Timing is affected by whether the ANDA is:
- under 505(j) with Paragraph IV certification
- subject to stays or court-ordered injunctions
- impacted by amendments, exclusivity carve-outs, or multiple strengths
These factors cannot be mapped to this case without the FDA-related filings and the reference-listed drug identity.
Key Takeaways
- Knoa Pharma, LLC sued Accord Healthcare Inc. in 5:24-cv-00284 in 2024 as a Hatch-Waxman-type patent infringement matter.
- The prompt does not provide the asserted patent numbers, Orange Book listings, infringement claim mappings, docket status, or disposition terms.
- A complete litigation summary and patent-claims analysis cannot be produced from the information provided.
FAQs
-
What should the complaint in 5:24-cv-00284 list to identify the asserted patents and claims?
The asserted Orange Book patents, specific claims, the accused ANDA product/dosage form, and infringement theories.
-
How does the 30-month stay typically interact with patent expiration in ANDA cases?
It can delay FDA approval until the stay lifts or is modified, but the exact effect depends on the triggering events and court outcomes.
-
What docket events indicate Markman (claim-construction) in Hatch-Waxman cases?
Scheduling orders setting claim construction, Markman dates, and submission of claim construction briefs.
-
What court filings confirm settlement in patent cases?
Stipulations of dismissal, consent judgments, or orders referencing settlement terms.
-
How do formulation vs method-of-use patents change infringement risk for a generic?
Formulation claims can turn on excipient/composition specifics; method-of-use claims hinge on the intended use instructions and how the product is prescribed/used.
References
- U.S. District Court, Eastern District of Texas, Knoa Pharma, LLC v. Accord Healthcare Inc., No. 5:24-cv-00284 (case number provided in prompt).
